Cetuximab: head and neck cancers: for second-line treatment, in combination with radiotherapy.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005602:France; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D018714:Radiotherapy, Adjuvant
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents